COVID-19: Vaccines and Therapeutics
FDA issues updated EUA for bivalent booster doses to fight omicron; providers to cease administration of monovalent boosters
Sep 1, 2022
The Food and Drug Administration yesterday announced it has amended the emergency use authorizations for Pfizer’s and Moderna’s COVID-19 vaccines to account for new, bivalent formulations designed to install immunity against the SARS-CoV-2 omicron variant.
Pfizer applies for EUA for variant-tailored booster; unveils new efficacy data for youngest children
Aug 23, 2022
Pfizer yesterday announced its application for an emergency use authorization for a COVID-19 vaccine booster that is designed to protect against the SARS-CoV-2 omicron variant. The booster is meant for the 12 and older age group.
Aug 22, 2022
Novavax today announced the Food and Drug Administration expanded the emergency use authorization for its Adjuvanted (NVX-CoV2373) COVID-19 vaccine. Under the expanded EUA, the two-dose primary series can be administered for adolescents between the ages of 12 and 17.
Aug 18, 2022
Riley Children’s Health is working to ensure that children, including those under age 5, get the COVID-19 vaccine, by hosting vaccine clinics across the Indianapolis area and ramping up access to the vaccine in pediatrician offices. The hospital also partnered with The Children’s Museum of…
Aug 18, 2022
While masks have been removed from most school supply lists this season, health care officials say new variants, such as BA.5, can spread quickly putting kids and families at risk.
Aug 12, 2022
To encourage Arkansas residents of all ages to get the COVID-19 vaccine and booster, Baptist Health has set up vaccine clinics across the state at banks, churches, schools, shopping malls and more.
Aug 9, 2022
Hospital leaders from the AHA’s vaccine confidence initiative share tips for building COVID-19 vaccine confidence.
Aug 8, 2022
This is a confusing time in the public health emergency. Americans are thinking less about COVID-19 on a daily basis and many are eager to move on.
Aug 5, 2022
What is Paxlovid? Paxlovid (ritonavir-boosted nirmatrelvir) is a preferred oral antiviral authorized for the treatment of mild-moderate COVID-19 illness. Patients take a combination of pills twice a day for 5 days. Paxlovid should be administered as early as possible following the…
Aug 1, 2022
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines.